“The insurance benefit of Velcade as the primary treatment is urgently required”

An opinion was stressed again that the insurance benefit of ‘Velcade(generic name: bortezomib)’ needs to be extended for multiple myeloma patients to use as the primary treatment.

On the 22^nd, Prefessor Jae-joong Lee of the department of internal medicine, Chonnam National University Hwasun Hospital, unveiled at the Velcade’s 10^th anniversary press conference that there are difficulties in the...